Antiangiogenic monotherapies, including targeting the VEGF pathway, resulted only in a modest normalization or failed completely (81, 82), and a promising targeting of ALK1 has recently not fulfilled the efficacy objective in phase II studies of patients with endometrial carcinoma (34) and metastatic squamous cell carcinoma (83). Here, ACVRL1 is linked to endometrial carcinoma.